– 3 Patients with PD-1 Refractory Cutaneous Melanoma are Responders Including One Complete Response (CR) – – Driven by Increased Prioritization of IMO-2125 Clinical Development, Company Suspends Development of IMO-8400 for B-Cell Lymphomas – CAMBRIDGE, Mass. and EXTON, Pa., Sept. 26, 2016 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing Toll-like receptor […]